OWL833, an orally active nonpeptide GLP-1 receptor agonist, improves glucose tolerance by increasing insulin secretion and reduces food intake of cynomolgus monkeys
Food and Drug Administration approval are not covered
Practical implementation considerations include: Post-meal activity : Even light walking (10-15 minutes) after meals may improve postprandial glucose levels Reducing sedentary time : Breaking up prolonged sitting with brief activity every 30 minutes Consistency over intensity : Regular moderate activity provides greater metabolic benefit than sporadic vigorous exercise Individualization : Exercise prescriptions should account for baseline fitness, comorbidities, and personal preferences to optimize adherence Special precautions are needed for those with diabetes complications, including proper footwear with neuropathy, avoiding high-impact or head-down exercises with retinopathy, and appropriate cardiovascular assessment before beginning vigorous exercise
Staying at a lower dose longer is a legitimate clinical strategy and often produces better tolerability with only modest reduction in weight loss speed
After 68 weeks, they lost almost 15% of their body weight
Seek medical advice if you are unable to keep fluids down or notice a significant reduction in urine output
